Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function by Lane, Hsien-yuan
Eﬀects of dopamine D2 receptor Ser311Cys
polymorphism and clinical factors on
risperidone eﬃcacy for positive and negative
symptoms and social function
Hsien-Yuan Lane1, Cheng-Chun Lee2, Yue-Cune Chang3, Chung-Ta Lu2,
Chiung-Hsien Huang1 and Wen-Ho Chang4
1 Department of Psychiatry, China Medical University and Hospital, Taichung, Taiwan, ROC
2 Department of Neurology, China Medical University and Hospital, Taichung, Taiwan, ROC
3 Institutes of Life Sciences and Mathematics, Tamkang University, Taipei, Taiwan, ROC
4 Department of Psychiatry, Tzu-Chi University, Hualien, Taiwan, ROC
Abstract
Risperidone is an atypical antipsychotic agent with eﬃcacy for both positive and negative symptoms of
schizophrenia. However, what makes an antipsychotic ‘atypical’ remains unclear. We recently found that
the T102C polymorphism in the 5-HT2A receptor gene could aﬀect risperidone’s eﬃcacy for negative
symptoms. The present study investigated the eﬀect of the Ser311Cys polymorphism in the dopamine D2
receptor (DRD2) gene on risperidone treatment response. A total of 123 Han Chinese patients with acutely
exacerbated schizophrenia were given risperidone for up to 42 days. Clinical manifestations were
measured bi-weekly with Positive and Negative Syndrome Scale (PANSS) and Nurses’ Observation Scale
for Inpatients Evaluation (NOSIE, for assessment of social function). For adjusting the within-subject
dependence over repeated assessments, multiple linear regression with generalized estimating equation
methods was utilized to analyse the eﬀects of Ser311Cys polymorphism and other covariates on clinical
performance. Compared with patients who had the Ser311Ser genotype, patients with the Ser311Cys
genotype had lower scores on PANSS Positive, Negative, General Psychopathology and Cognitive
subscales and NOSIE, after adjustment for 5-HT2A T102C polymorphisms and other confounders. The
5-HT2A T102C polymorphism had marginal inﬂuences on PANSS Total and Negative subscale scores.
Male gender, fewer previous hospitalizations, and higher risperidone dose predicted better treatment
response after control for other variables. The preliminary results suggest that variations in the DRD2
gene inﬂuence risperidone treatment response for positive, negative, and cognitive symptoms, general
psychopathology, and social functioning. Several clinical factors may also contribute to inter-individual
diﬀerences in risperidone treatment response.
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Introduction
Schizophrenia is a chronic mental disorder and its
symptoms are primarily subdivided into two sub-
types, positive and negative (Andreasen, 1985 ; Chang
et al., 1990). The positive symptoms include delusions
and hallucinations ; the negative symptoms, blunted
aﬀect and social withdrawal. Later factor analysis
studies also revealed another syndrome factor (dis-
organization) (Marengo et al., 2000 ; Toomey et al.,
1998). The treatment of schizophrenic patients with a
typical antipsychotic or an atypical antipsychotic has
been successful against positive symptoms. A main
question is whether atypical agents are superior in the
treatment of negative symptoms than typical agents
(Leucht et al., 1999, 2003).
Although atypical antipsychotics are becoming the
mainstay for schizophrenia treatment, what makes an
antipsychotic ‘atypical’ remains unclear (Emilien et al.,
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1999; Meltzer, 1999 ; Sawa and Snyder, 2002). Part of
the reason for this lack of clarity is the limited number
of appropriate animal models that can model schizo-
phrenia symptoms and that can be used for drug
screening (Corbett et al., 1993 ; Ellenbroek et al., 1989;
Pouzet et al., 2002). Thus, it is of great importance to
determine how antipsychotics improve symptom do-
mains in patients with schizophrenia. A balance of 5-
HT2A-receptor occupancy and dopamine D2-receptor
occupancy probably underlies the beneﬁcial thera-
peutic action of risperidone, especially on negative
symptoms (Leysen et al., 1994). In agreement, our
recent study (Lane et al., 2002a) demonstrated that
variations in the 5-HT2A receptor gene could inﬂuence
risperidone treatment response (particularly for nega-
tive symptoms rather than positive symptoms). Of
note, it has been proposed that the atypical anti-
psychotic eﬀect can be produced by appropriate
modulation of the dopamine D2 receptor (DRD2)
alone ; the blockade of other receptors is neither
necessary nor suﬃcient (Kapur et al., 2000).
Several polymorphisms have been described in the
DRD2 gene (Arranz et al., 1998a; Itokawa et al., 1993;
Schafer et al., 2001). Of them, x141C Ins/Del (in the
promoter region) (Arranz et al., 1998a; Malhotra and
Goldman, 1999 ; Yamanouchi et al., 2003) and TaqI
(a silent variant) (Yamanouchi et al., 2003) have been
examined for their association with eﬃcacy of atypi-
cal antipsychotics. Arranz et al. (1998a) studied the
x141C Ins/Del polymorphism in a sample of 151
clozapine- (the prototype of atypical antipsychotics)
treated patients of British origin and in another sample
of 146 Han Chinese schizophrenic patients treated
with a variety of antipsychotics. No association was
found between this polymorphism and clinical re-
sponse in either of the two samples. Malhotra and
Goldman (1999) detected an association between this
polymorphism and clozapine response ; however,
the number and characteristics of the subjects were
undisclosed. Yamanouchi et al. (2003) examined six
candidate polymorphisms (includingDRD2x141delC
and TaqI) in 73 Japanese patients who were given
risperidone treatment. A DRD2 haplotype tended to
correlate with better clinical performance. Compared
with patients who had Ins-A2/Ins-A2 diplotype (n=
25), patients with Ins-A2/Del-A1 diplotype (n=10)
showed greater improvement.
Moreover, there is a missense variant of the DRD2
gene resulting in a substitution of serine with cysteine
at codon 311 (Ser311Cys) (Itokawa et al., 1993). Ser311
lies in the middle portion of the third intracellular loop
of the short form of the DRD2, which can modulate or
take part in the receptor–G-protein interaction. It has
been shown that risperidone, unlike several other anti-
psychotics, has no diﬀerences in binding aﬃnities and
potencies for this DRD2 variant (Cravchik et al., 1999).
The Cys311 variant, however, was markedly less
eﬀective in inhibiting cAMP synthesis than the more
prevalent form (Ser311) (Cravchik et al., 1996). Re-
placement of Ser311 with Cys311 might also aﬀect
the regulation of desensitization and internalization of
the receptor (Itokawa et al., 1996), or it might produce
a conformational change of the receptor protein by
forming a new disulphide bond (Arinami et al., 1994).
Functional diﬀerences between DRD2 variants may,
thus, be related to genetically determined diﬀerences
in response to antipsychotic treatment.
Antecedent studies showed that, when treated
with typical antipsychotics, patients carrying Cys311
had shorter duration of past and current admission
(Arinami et al., 1994) orwere less likely to be treatment-
resistant to typical agents (Shaikh et al., 1994) than
those without Cys311. In the Shaikh et al. (1994) study
only two treatment-resistant patients carried the
Cys311 allele and both individuals responded to sub-
sequent clozapine treatment. Therefore, whether this
polymorphism inﬂuences antipsychotics (particularly
atypicals) eﬃcacy for positive or negative symptoms
deserves further investigation.
Most of the previous genetic-response studies
on neurotransmitter receptors or transporters cannot
be reconﬁrmed (Arranz et al., 2000 ; Malhotra and
Goldman, 1999 ; Masellis et al., 2000 ; Staddon et al.,
2002). These pharmacogenetic studies did not usually
take into account other determinants such as gender,
age, education level, diagnosis subtype, age at illness
onset, duration of illness, and hospitalization history
(Lane et al., 2002b; Lieberman et al., 1994). The current
study aimed to explore the inﬂuence of the DRD2
Ser311Cys polymorphism on risperidone response
for positive and negative symptoms and social func-
tion after adjustment for the eﬀects of treatment
duration, baseline psychopathology, drug dose, and
other patient-related variables. Since the 5-HT2A
T102C polymorphism could also inﬂuence risperidone
response for negative symptoms (Lane et al., 2002a),
this genetic factor was also taken into account.
Method
Subjects
This prospective, open-labelled, and repeated-
measures study was conducted in the in-patient unit
of China Medical University Hospital. The protocol
was approved by the Institution’s Review Board and
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carried out in accordance with Declaration of Helsinki.
All newly hospitalized schizophrenic patients with
acute exacerbation were screened and evaluated by
experienced psychiatrists. The Structured Clinical
Interview for DSM-IV (APA, 1994) was conducted for
the diagnosis. Han Chinese patients in Taiwan entered
into this study if they (1) were physically healthy and
had all laboratory parameters within normal limits, (2)
were aged 18–60 yr, (3) satisﬁed DSM-IV criteria for
schizophrenia, (4) had a minimum baseline total score
of 60 on the Positive and Negative Syndrome Scale
(PANSS; Kay et al., 1987), (5) had neither current nor
past DSM-IV diagnosis of mood disorders or substance
(including alcohol) abuse, (6) were non-smokers, (7)
had not received depot antipsychotics during the pre-
ceding 6 months, (8) had no history suggesting that
antipsychotic treatment would be contraindicated,
and (9) had never received atypical antipsychotics
before. After complete description of the study to the
subjects, written informed consent was obtained in
line with the Institution’s Review Board guidelines.
Study design and intervention
During the washout period, the subjects were placed
on a placebo for 7 d, which could be shortened to a
minimum of 1 d for patients with extremely emergent
psychotic symptoms. Then, during the risperidone
monotherapy period, the drug dose was gradually
titrated to the target dose 6 mg/d (or lower, in case of
intolerance) within 1 wk. From day 8 to day 42, the
dosage remained the same as that used on day 7, or
could be reduced on day 14 or day 28 after the drug-
safety evaluation (see ‘Assessments’ below). Nursing
staﬀ closely monitored and ensured the patients’
compliance. The dosing strategy was based upon our
recent work (Lane et al., 2000) : nearly 60% of 30 acute
schizophrenia in-patients tolerated a target dose of
6 mg/d; for the other 40% of patients, reducing doses
to a mean of 3.6 mg/d for the relief of side-eﬀects still
yielded eﬃcacy.
Assessments
Drug eﬃcacy and safety assessments were conducted
on days 0, 14, 28 and 42. An experienced research
psychiatrist (H.-Y.L.), unaware of the genotypes of
the patients, administered all eﬃcacy and safety
rating instruments. Patients’ symptoms were assessed
by the PANSS and its Positive, Negative, and General
Psychopathology subscales (Kay et al., 1987). In ad-
dition, the PANSS has a ‘Cognitive’ subscale, which
also somewhat represents ‘disorganization of thought
and behaviour’ and consists of ﬁve items: conceptual
disorganization, diﬃculty in abstract thinking, man-
nerism and posturing, disorientation, and lack of
judgement and insight (Lindenmayer et al., 1994).
Social functioning and activities of daily living were
determined by the Nurses’ Observation Scale for
Inpatients Evaluation (NOSIE; Honigfeld and Klett,
1965). The NOSIE thus complements the PANSS (that
focuses more on psychopathology). Drug safety was
evaluated by routine physical and neurological exam-
inations, laboratory tests, the Extrapyramidal Symp-
tom Rating Scale (ESRS; Chouinard et al., 1980), and
the Udvalg for Kliniske Underso-gelser (UKU) Side
Eﬀect Rating Scale (Lingjaerde et al., 1987). The ESRS
was designed to evaluate three types of extrapyramidal
symptoms: parkinsonism, dystonia, and dyskinesia
(Chouinard et al., 1980). Other side-eﬀect proﬁles were
determined by the UKU Scale.
Genotyping
Patients were genotyped for DRD2 and 5-HT2A
polymorphisms by polymerase chain reaction ampli-
ﬁcation of DNA and then digestion with Sau96I for
detection of Ser311Cys (Arinami et al., 1994) and with
MspI for detection of T102C (Chen et al., 1997). DNA
fragments were visualized by 2% agarose gel electro-
phoresis and staining with ethidium bromide.
Statistical analysis
For between-group comparisons, two-tailed x2 tests
or Fisher’s exact tests were used for categorical data,
while two-tailed Mann–Whitney U tests were used
for dimensional data. For within-group comparisons,
two-tailed Wilcoxon Signed Ranks tests were used
for dimensional data. These non-parametric statistical
methods were used because the distributions of the
dependent measures were not normally distributed.
The main purpose of this study, however, was to
examine the association between the DRD2 Ser311Cys
polymorphism and risperidone eﬀectiveness after con-
trolling for other variables. PANSS Total and subscales
scores and NOSIE total score were used as measures of
response to risperidone. Potential prognostic factors
included DRD2 and 5-HT2A polymorphisms as well
as treatment duration (weeks 0–6), baseline PANSS
subscale or NOSIE score, end-point risperidone dose,
gender, age, education level, diagnosis subtype, age
at illness onset, duration of illness, and number of
previous hospitalizations. To evaluate the possible
eﬀects of the prognostic factors on the response values,
the multiple linear regression model, which is cap-
able of controlling for other prognostic factors, was
utilized.
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Because multiple linear regression can be applied
only if the distribution of the response values is
symmetrical (Bolton, 1984), we examined the distri-
bution patterns of the PANSS or NOSIE scores, using
the ‘Kolmogorov D’ package in SAS/INSIGHT, version 8.2
(SAS Institute Inc., 1999). We found that the distri-
butions of these scores in our subjects were skewed
to right. Since logarithmic transformation can convert
the skew-to-right distribution to a normal distri-
bution (Bolton, 1984 ; Lane et al., 1999a), the value
of each PANSS Total or subscale score or the NOSIE
total score was transformed to its natural logarithm
to obtain a normal distribution prior to multiple re-
gression analyses. For example, the value of testing
statistics for distribution of PANSS Total scores was
0.068 (p<0.01) and for distribution of natural log-
arithms of PANSS Total scores was 0.0368 (p=0.128).
The result with a p value >0.05 means the data are
more likely to be normally distributed. Therefore, the
PANSS Total scores were not likely to be normally
distributed but the natural logarithms of the PANSS
Total scores were more likely to be.
Another basic requirement for conventional mul-
tiple linear regression is that the collected data should
be independent. In other words, each subject should
provide one and only one record in the dataset. For
repeated-measures studies (such as the current one),
the longitudinal follow-up data obtained from the
same subject, however, are intra-individually re-
lated and violate the ‘independent’ requirement. To
adjust this within-subject dependence eﬀect, Zeger
et al. (1988) set up a statistical method named the
generalized estimating equation for multiple linear
regression in repeated-measures studies. In the cur-
rent study, we thus conducted the generalized esti-
mating equation analysis, using SAS/STAT, version 8.2
(SAS Institute Inc., 1999), to control for time eﬀects,
baseline psychopathology, and other patient-related
variables. Statistical signiﬁcance was deﬁned as
p<0.05. Bonferroni correction seemed inappropriate
in the current case because several of the dependent
measures were inter-correlated.
Results
Patient disposition and characteristics
In total, 123 patients at least completed the assess-
ments on days 0 and 14 (the ﬁrst post-treatment visit)
and were eligible for data analysis. The number of
patients actively participating on days 28 and 42 were
117 and 102 respectively. The reasons for premature
discontinuation were concurrent somatic illness (n=
2), suﬃcient response (n=11), poor response (n=4),
and non-compliance (n=4). The mean age of the
123 patients was 34.0¡9.7 yr (68 male, 55 female).
The mean¡S.D. age at illness onset was 24.5¡7.9 yr,
the mean illness duration was 105.6¡85.0 months, the
mean number of previous hospitalizations was 1.9¡
2.5, and the mean level of education was 10.7¡2.9 yr.
The distribution of subtypes was 86 paranoid, 14
disorganized, and 23 undiﬀerentiated. Thirty-one
patients did not tolerate the target dose of 6 mg/d and
the mean risperidone dose in all 123 subjects at end-
point was 4.0¡1.4 mg/d. Since our dosing strategy
was to reduce side-eﬀects if possible, adverse events in
the subjects were minimal (if any), short-lived, and
resolved spontaneously or after dose reduction, with-
out requiring medical treatment. No clinically signiﬁ-
cant and relevant abnormal laboratory test results
were recorded. No patients withdrew from the trial
due to adverse reactions.
As shown in Table 1, the two DRD2 genotype
groups were similar in demographics. The genotype
distribution was Ser/Ser in 111 patients and Ser/Cys
in 12 patients. No Cys/Cys patients were found. The
allele frequency of Cys311 was similar to that in other
studies enrolling Japanese (Arinami et al., 1994; Hori
Table 1. Demographics (mean¡S.D.) in patients with Ser/Ser or Ser/Cys genotype
Ser/Ser Ser/Cys p value
Age (yr) 33.8¡9.6 33.0¡11.9 0.673
Age at illness onset (yr) 24.5¡8.0 25.0¡7.6 0.669
Illness duration (months) 106.3¡84.6 99.6¡92.1 0.588
Number of previous hospitalizations 2.0¡2.5 1.3¡2.1 0.226
Duration of education (yr) 10.7¡3.0 11.2¡1.8 0.654
Diagnostic subtypes (paranoid/
disorganized/undiﬀerentiated)
78/14/19 8/0/4 0.217
Two-tailed x2 tests or Fisher’s exact tests for categorical data ; two-tailed
Mann–Whitney U tests for dimensional data.
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et al., 2001) but somewhat higher than that in the
Western populations (Gejman et al., 1994 ; Shaikh et al.,
1994 ; Spurlock et al., 1998). The 5-HT2A genotype
distribution was T/T in 54 patients, C/C in 12, and
T/C in 57. The allele frequency of T102 was similar
to that in the earlier study with Han Chinese (Corbett
et al., 1993) but higher than that in Western individ-
uals (Arranz et al., 1998b; Williams et al., 1996).
Determinants for clinical performance
The mean¡S.D. PANSS Total scores declined during
risperidone treatment : 89.4¡16.2 at baseline and
70.0¡16.0 at end-point. The mean Positive subscale
scores declined from 23.6¡4.3 to 17.0¡5.1. The mean
Negative scores declined from 26.2¡5.8 to 22.0¡5.8,
the General Psychopathology scores declined from
39.7¡9.0 to 31.2¡7.8, the Cognitive scores declined
from 14.7¡4.3 to 11.5¡3.7, and the NOSIE total scores
declined from 70.6¡12.2 to 57.7¡11.3. All these scores
declined signiﬁcantly (all p values=0.000).
As shown in Table 2, the two DRD2 genotype
groups were similar in all baseline clinical measures.
From baseline to study end-point, the Ser/Cys group
of patients had signiﬁcantly larger score reductions
and percentage changes in negative symptoms than
their counterparts (p=0.011 and 0.023 respectively).
The Ser/Cys patients also had numerically (albeit
statistically insigniﬁcant) larger score reductions and
percentage changes at end-point in all other domains
(particularly, p<0.1 for score reductions in PANSS
Total and General Psychopathology as well as per-
centage changes in PANSS Total and Negative and
Cognitive subscales, and NOSIE).
As shown in Table 3, after adjustment for treatment
time eﬀects, baseline psychopathology, risperidone
dose, the 5-HT2A T102C polymorphism, and other
patient-related variables, the Ser311Cys polymor-
phism could inﬂuence performances in PANSS
Total and subscales and in NOSIE: the Ser/Cys geno-
type was related with lower scores on all rating scales
than the Ser/Ser genotype. In details, compared with
Table 2. Score changes and percentage changes (mean¡S.D.) from baseline
to end-point in the Positive and Negative Syndrome Scale (PANSS) and
Nurses’ Observation Scale for Inpatients Evaluation (NOSIE) in patients with
Ser/Ser or Ser/Cys genotype
Ser/Ser Ser/Cys p value
PANSS Total scale
Baseline score 89.1¡16.9 92.8¡7.2 0.161
Score change at end-point 18.8¡14.7 26.2¡11.9 0.087
Percent change at end-point 20.4¡13.6 28.0¡11.8 0.096
PANSS Positive subscale
Baseline score 23.8¡4.2 22.4¡5.3 0.166
Score change at end-point 6.5¡4.2 8.0¡5.5 0.745
Percent change at end-point 27.5¡16.4 33.3¡16.5 0.498
PANSS Negative subscale
Baseline score 26.0¡6.0 28.4¡3.4 0.110
Score change at end-point 3.9¡5.2 6.9¡3.7 0.011
Percent change at end-point 14.1¡17.3 24.2¡12.3 0.023
PANSS General Psychopathology
Baseline score 39.5¡9.4 41.9¡4.8 0.143
Score change at end-point 8.2¡7.1 11.4¡4.4 0.063
Percent change at end-point 20.0¡15.3 27.7¡11.4 0.147
PANSS Cognitive subscale
Baseline score 14.7¡4.4 14.5¡3.1 0.990
Score change at end-point 3.1¡3.4 4.2¡2.6 0.196
Percent change at end-point 18.9¡19.2 28.6¡15.4 0.067
NOSIE
Baseline score 70.6¡12.3 70.2¡11.0 0.818
Score change at end-point 12.9¡9.7 16.8¡9.6 0.235
Percent change at end-point 17.0¡11.6 23.3¡9.9 0.066
Two-tailed Mann–Whitney U tests.
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Table 3. Eﬀects of treatment duration, baseline psychopathology, end-point risperidone dose, gender, number of previous
hospitalizations, the 5-HT2A T102C polymorphism, and the DRD2 Ser311Cys polymorphism of the DRD2 gene on Positive
and Negative Syndrome Scale (PANSS) Total and subscales scores and Nurses’ Observation Scale for In-patients Evaluation
(NOSIE) score
Relation to natural logarithm score on PANSS and NOSIE
Estimated coeﬃcient Standard error p value
PANSS Total scale
Treatment duration (1-wk increments) x0.0322 0.0035 <0.0001
Baseline total scale score 0.8159 0.0704 <0.0001
Dose (1-mg increments) x0.0178 0.0030 <0.0001
Male compared with female x0.0482 0.0156 0.002
Number of previous hospitalizations 0.0122 0.0046 0.008
5-HT2A T/T genotype compared with T/C 0.0002 0.0177 0.991
5-HT2A C/C genotype compared with T/C x0.0614 0.0314 0.050
DRD2 Ser/Ser genotype compared with Ser/Cys 0.0748 0.0242 0.002
PANSS Positive subscale
Treatment duration (1-wk increments) x0.0454 0.0046 <0.0001
Baseline positive subscale score 0.9109 0.0576 <0.0001
Dose (1-mg increments) x0.0260 0.0042 <0.0001
Male compared with female x0.0531 0.0214 0.013
Number of previous hospitalizations 0.0232 0.0049 <0.0001
5-HT2A T/T genotype compared with T/C x0.0180 0.0223 0.419
5-HT2A C/C genotype compared with T/C x0.0590 0.0515 0.251
DRD2 Ser/Ser genotype compared with Ser/Cys 0.0962 0.0380 0.011
PANSS Negative subscale
Treatment duration (1-wk increments) x0.0249 0.0042 <0.0001
Baseline negative subscale score 0.8208 0.0658 <0.0001
Dose (1-mg increments) x0.0108 0.0040 0.007
Male compared with female x0.0681 0.0208 0.001
Number of previous hospitalizations 0.0039 0.0052 0.454
5-HT2A T/T genotype compared with T/C x0.0046 0.0224 0.838
5-HT2A C/C genotype compared with T/C x0.0806 0.0420 0.055
DRD2 Ser/Ser genotype compared with Ser/Cys 0.0822 0.0354 0.020
PANSS General Psychopathology
Treatment duration (1-wk increments) x0.0313 0.0035 <0.0001
Baseline general psychopathology score 0.8210 0.0487 <0.0001
Dose (1-mg increments) x0.0173 0.0034 <0.0001
Male compared with female x0.0340 0.0160 0.033
Number of previous hospitalizations 0.0118 0.0047 0.013
5-HT2A T/T genotype compared with T/C 0.0109 0.0192 0.571
5-HT2A C/C genotype compared with T/C x0.0383 0.0276 0.166
DRD2 Ser/Ser genotype compared with Ser/Cys 0.0627 0.0272 0.021
PANSS Cognitive subscale
Treatment duration (1-wk increments) x0.0336 0.0040 <0.0001
Baseline negative subscale score 0.8069 0.0467 <0.0001
Dose (1-mg increments) x0.0128 0.0035 0.0003
Male compared with female x0.0343 0.0189 0.070
Number of previous hospitalizations 0.0093 0.0057 0.103
5-HT2A T/T genotype compared with T/C 0.0300 0.0238 0.206
5-HT2A C/C genotype compared with T/C x0.0521 0.0427 0.223
DRD2 Ser/Ser genotype compared with Ser/Cys 0.1083 0.0361 0.003
NOSIE
Treatment duration (1-wk increments) x0.0253 0.0027 <0.0001
Baseline NOSIE score 0.7880 0.0428 <0.0001
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patients who had the Ser/Cys genotype, the PANSS
Total scores of patients with the Ser/Ser genotypewere
7.77% higher (e0.0748=1.0777, 1.0777x1=0.0777), their
Positive subscale scores were 10.10% higher (e0.0962=
1.1010), their Negative subscale scores were 8.57%
higher (e0.0822=1.0857), their General Psychopathology
scores were 6.47% higher (e0.0627=1.0647), their Cog-
nitive subscale scores were 11.44% higher (e0.1083=
1.1144), and their NOSIE total scores were 6.69%
higher (e0.0648=1.0669). If we controlled for all above-
mentioned variables but excluded 5-HT2A T102C poly-
morphisms, the patients with the Ser/Cys genotype
still had signiﬁcantly better performance on all as-
sessments than the wild-type individuals (results not
shown).
The 5-HT2A T102C polymorphism also hadmarginal
inﬂuences on PANSS Total and Negative subscale
scores (Table 3). Compared to patients who had the
T/C genotype, those with C/C genotype had numeri-
cally (albeit statistically insigniﬁcant) lower scores in
the PANSS Total (p=0.050) and the Negative subscale
(p=0.055), but not in the Positive subscale or other
scales. T/C and T/T genotypes were comparable in
each PANSS subscale or NOSIE score. As also shown
in Table 3, higher end-point dose of risperidone, male
gender, and fewer previous hospitalizations also pre-
dicted better clinical performance.
Further analysis revealed that the patients with the
Ser/Cys genotype had a higher female to male ratio
(9/3) than those with Ser/Ser (46/65) (p=0.034). The
heterozygote group also tended to tolerate lower ris-
peridone doses compare to the wild-type group (3.3¡
1.2 mg/d vs. 4.1¡1.4 mg/d, p=0.071). These diﬀer-
ences, however, should not have contributed to the
superior clinical performance of the Ser/Cys patients
because regression analyses, as shown above, revealed
that female patients and lower doses were associated
with inferior response to risperidone.
Discussion
To our knowledge, the present study is the ﬁrst to
investigate an association between atypical anti-
psychotic eﬀects and the Ser311Cys polymorphism in
the DRD2 gene. We found that, compared to the
Ser311Ser genotype, the Ser311Cys genotype was
associated with superior risperidone response (for
positive, negative, and cognitive symptoms, general
psychopathology, and even social function) in patients
with acutely exacerbated schizophrenia. Our study
results support the ﬁndings of previous studies
(Arinami et al., 1994 ; Shaikh et al., 1994) : when treated
with typical antipsychotics, patients carrying Cys311
had shorter duration of hospitalization or were less
likely to be treatment-resistant than those without
Cys311. Arinami et al. (1994) also found the DRD2 Cys
allele to be a risk factor schizophrenia. Although a
large number of replication attempts have failed, two
recent meta-analyses (Glatt et al., 2003 ; Jonsson et al.,
2003) substantiate the notion that the DRD2 Cys allele
may be a risk factor for the development of schizo-
phrenia. Taken together, these results support the
involvement of the DRD2 gene in the pathogenesis
of schizophrenia and perhaps treatment response of
antipsychotics.
In accordance with our earlier ﬁnding in 100
patients (Lane et al., 2002a), the current study in
an extended sample showed that the 5-HT2A T102C
polymorphism could aﬀect PANSS Total and Negative
subscale scores (but not Positive subscale scores) with
borderline signiﬁcance. Although the T102C substi-
tution does not alter amino-acid sequence, recent evi-
dence (Polesskaya and Sokolov, 2002) indicates that
total levels of 5-HT2A receptor mRNA and protein in
normal individuals with the C/C genotype are lower
than in individuals with the T/T genotype.
Certainly, we might have had a chance false-
Table 3 (cont.)
Relation to natural logarithm score on PANSS and NOSIE
Estimated coeﬃcient Standard error p value
Dose (1-mg increments) x0.0156 0.0030 <0.0001
Male compared with female x0.0111 0.0164 0.500
Number of previous hospitalizations 0.0103 0.0031 0.0009
5-HT2A T/T genotype compared with T/C 0.0100 0.0141 0.481
5-HT2A C/C genotype compared with T/C x0.0311 0.0252 0.217
DRD2 Ser/Ser genotype compared with Ser/Cys 0.0648 0.0157 <0.0001
Multiple linear regression with the generalized estimating equation method.
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positive ﬁnding. Although 123 subjects is a fairly
robust sample size for a pharmacogenetic study, the
low frequency of the Ser311Cys polymorphism results
in a comparison of only 12 Ser/Cys heterozygotes to
111 Ser/Ser homozygotes (with no Cys/Cys homo-
zygotes). Any conclusions drawn from this study
should be tempered by the small sample of patients
with the rarer allele. We thus consider the results to be
preliminary. Moreover, the genetic eﬀect on negative
symptoms might have been secondary to the genetic
eﬀect on positive symptoms (Kane, 1994 ; Lane et al.,
1999b). Further studies in other ethnic populations, in
chronically ill patients receiving long-term treatment
(Masellis et al., 2000 ; Rietschel et al., 1999), and in
patients with predominantly negative symptoms
(Lane et al., 1999b) are warranted. Possible eﬀects of
other DRD2 polymorphisms, such as x141C Ins/Del
(Arranz et al., 1998a; Malhotra and Goldman, 1999;
Suzuki et al., 2001; Yamanouchi et al., 2003) and TaqI
(Schafer et al., 2001 ; Yamanouchi et al., 2003), on ris-
peridone eﬃcacy also require investigation. Finally,
since risperidone also has eﬀects on dopamine D4,
histamine H1, adrenergic a1 and a2 (Meltzer, 1999), and
5-HT1A and 5-HT2C receptors (Ichikawa et al., 2001;
Tarazi et al., 2002), the genetic eﬀects of various re-
ceptors on risperidone eﬃcacy should also be clariﬁed
(Kroeze and Roth, 1998).
In the current study, comorbidmood disorders were
considered as exclusion criteria. Since DRD2 poly-
morphisms have been studies in pharmacogenetic
studies in aﬀective disorders (Serretti et al., 1999, 2001)
and risperidone has been shown to have an anti-
depressant activity (Lane and Chang, 1998 ; Myers and
Thase, 2001), further pharmacogenetic studies regard-
ing mood eﬀects of risperidone and polymorphisms
of the DRD2 (or other receptors) may be of interest.
In an earlier study (Lane et al., 1999b) without con-
trolling for Ser311Cys, gender eﬀects on risperidone
eﬃcacy did not achieve statistical signiﬁcance. In the
current study, male patients responded better to ris-
peridone than female patients after adjustment for the
eﬀects of genotypes and other patient-related vari-
ables. Similarly, schizophrenic males may be more
likely to be good responders to clozapine (the proto-
type of atypical antipsychotics) than females (Lieber-
man et al., 1994). Therefore, gender inﬂuences on
treatment response may be diﬀerent between atypical
antipsychotics and typical ones (Lieberman et al.,
1996). The current study also revealed that higher ris-
peridone dose (up to 6 mg/d, if tolerable) was related
with better treatment response for both positive and
negative symptoms. Further studies are needed.
There are several strengths in this study. We
evaluated the therapeutic response directly from
scores in the PANSS subscales and NOSIE rather
than dichotomizing the patients into responders and
non-responders, because response to antipsychotics is
not pharmacogenetically dichotomous. Furthermore,
instead of determining general response, positive,
negative, and cognitive symptoms and social func-
tioning were individually measured. Further, we
controlled for other covariates such as treatment
duration, baseline clinical manifestations, drug dos-
age, and other patient-related variables. We hope that
this rigorous model could reﬁne future pharmaco-
genetic or relevant genetic studies in neuropsychiatry.
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